Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 4.4% – What’s Next?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 4.4% on Thursday . The stock traded as low as $8.21 and last traded at $8.39. 277,918 shares traded hands during trading, a decline of 85% from the average session volume of 1,841,918 shares. The stock had previously closed at $8.78.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on OCUL. Robert W. Baird decreased their price objective on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. HC Wainwright increased their price objective on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, Scotiabank initiated coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.71.

Ocular Therapeutix Price Performance

The stock has a market capitalization of $1.34 billion, a P/E ratio of -6.61 and a beta of 1.26. The business’s 50 day simple moving average is $9.90 and its two-hundred day simple moving average is $8.09. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in OCUL. Atlas Capital Advisors LLC bought a new position in shares of Ocular Therapeutix in the second quarter valued at $34,000. Amalgamated Bank lifted its position in shares of Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,481 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,015 shares in the last quarter. Algert Global LLC bought a new position in shares of Ocular Therapeutix during the second quarter valued at about $69,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Ocular Therapeutix during the third quarter valued at about $70,000. 59.21% of the stock is owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.